BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nat Rev Microbiol 2007;5:952-8. [PMID: 17965726 DOI: 10.1038/nrmicro1769] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Vassileva-Pencheva R, Galabov AS. Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice. Antiviral Res 2010;85:366-72. [PMID: 19900482 DOI: 10.1016/j.antiviral.2009.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Korotkova E, Laassri M, Zagorodnyaya T, Petrovskaya S, Rodionova E, Cherkasova E, Gmyl A, Ivanova OE, Eremeeva TP, Lipskaya GY, Agol VI, Chumakov K. Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications. Viruses 2017;9:E353. [PMID: 29165333 DOI: 10.3390/v9110353] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
3 Stoyanova A, Nikolova I, Galabov AS. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice. Antiviral Res 2015;121:138-44. [PMID: 26196747 DOI: 10.1016/j.antiviral.2015.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Angez M, Shaukat S, Alam MM, Sharif S, Khurshid A, Zaidi SS. Genetic relationships and epidemiological links between wild type 1 poliovirus isolates in Pakistan and Afghanistan. Virol J 2012;9:51. [PMID: 22353446 DOI: 10.1186/1743-422X-9-51] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
5 Bachelder EM, Beaudette TT, Broaders KE, Paramonov SE, Dashe J, Fréchet JM. Acid-degradable polyurethane particles for protein-based vaccines: biological evaluation and in vitro analysis of particle degradation products. Mol Pharm 2008;5:876-84. [PMID: 18710254 DOI: 10.1021/mp800068x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
6 Khan MU, Ahmad A, Aqeel T, Akbar N, Salman S, Idress J. A Cross-Sectional Survey of Healthcare Workers on the Knowledge and Attitudes towards Polio Vaccination in Pakistan. PLoS One 2015;10:e0142485. [PMID: 26559184 DOI: 10.1371/journal.pone.0142485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013;33:606-46. [PMID: 23550968 DOI: 10.1111/risa.12031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
8 Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008;47:1587-92. [PMID: 18990066 DOI: 10.1086/593310] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
9 Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012;11:609-28. [PMID: 22827246 DOI: 10.1586/erv.12.28] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
10 Whitty C, Gosling R. Implications of attempts to eliminate malaria for front-line clinicians. Trop Doct 2008;38:1-2. [PMID: 18302847 DOI: 10.1258/td.2008.080013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Nathanson N. Eradication of poliovirus: fighting fire with fire. J Infect Dis 2011;203:889-90. [PMID: 21402539 DOI: 10.1093/infdis/jiq148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Griffin DE. Emergence and re-emergence of viral diseases of the central nervous system. Prog Neurobiol 2010;91:95-101. [PMID: 20004230 DOI: 10.1016/j.pneurobio.2009.12.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
13 Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol 2012;93:457-74. [PMID: 22128250 DOI: 10.1099/vir.0.036988-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
14 Hamidi A, Bakker WA. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Pat Anal 2012;1:589-99. [PMID: 24236927 DOI: 10.4155/ppa.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
15 Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses. PLoS One 2010;5:e12499. [PMID: 20824074 DOI: 10.1371/journal.pone.0012499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Famulare M, Chang S, Iber J, Zhao K, Adeniji JA, Bukbuk D, Baba M, Behrend M, Burns CC, Oberste MS. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria. J Virol 2016;90:317-31. [PMID: 26468545 DOI: 10.1128/JVI.01532-15] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
17 Agol VI. In pursuit of intriguing puzzles. Virology 2020;539:49-60. [PMID: 31670219 DOI: 10.1016/j.virol.2019.10.006] [Reference Citation Analysis]
18 Lenarcic EM, Landry DM, Greco TM, Cristea IM, Thompson SR. Thiouracil cross-linking mass spectrometry: a cell-based method to identify host factors involved in viral amplification. J Virol 2013;87:8697-712. [PMID: 23740976 DOI: 10.1128/JVI.00950-13] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
19 Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D. Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine. PLoS Pathog 2016;12:e1005483. [PMID: 27032093 DOI: 10.1371/journal.ppat.1005483] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
20 Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009;8:1083-97. [PMID: 19627189 DOI: 10.1586/erv.09.61] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 6.0] [Reference Citation Analysis]
21 Khan MU, Ahmad A, Aqeel T, Salman S, Ibrahim Q, Idrees J, Khan MU. Knowledge, attitudes and perceptions towards polio immunization among residents of two highly affected regions of Pakistan. BMC Public Health 2015;15:1100. [PMID: 26541976 DOI: 10.1186/s12889-015-2471-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
22 Heinsbroek E, Ruitenberg EJ. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010;28:3778-83. [DOI: 10.1016/j.vaccine.2010.02.095] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
23 Zangwill KM, Yeh SH, Wong EJ, Marcy SM, Eriksen E, Huff KR, Lee M, Lewis EM, Black SB, Ward JI. Paralytic Syndromes in Children: Epidemiology and Relationship to Vaccination. Pediatric Neurology 2010;42:206-12. [DOI: 10.1016/j.pediatrneurol.2009.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
24 Green MS, LeDuc J, Cohen D, Franz DR. Confronting the threat of bioterrorism: realities, challenges, and defensive strategies. Lancet Infect Dis 2019;19:e2-e13. [PMID: 30340981 DOI: 10.1016/S1473-3099(18)30298-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
25 Kelly DM. A Foot to Last a Lifetime-Is Hindfoot Fusion Ever Appropriate for Pediatric Orthopaedic Conditions? J Pediatr Orthop 2021;41:S39-46. [PMID: 34096536 DOI: 10.1097/BPO.0000000000001777] [Reference Citation Analysis]
26 Kunisawa J, Nochi T, Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol 2008;29:505-13. [PMID: 18835748 DOI: 10.1016/j.it.2008.07.008] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
27 Bisgin A, Sanlioglu AD, Eksi YE, Griffith TS, Sanlioglu S. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Hum Gene Ther 2021;32:541-62. [PMID: 33858231 DOI: 10.1089/hum.2021.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Nates SV, Frias M, Belfiore S, Isa MB, Martinez LC, Chuit R, Armoni J, Luxemburger C. Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city. Epidemiol Infect 2011;139:826-35. [DOI: 10.1017/s0950268810001512] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Famulare M, Selinger C, McCarthy KA, Eckhoff PA, Chabot-Couture G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLoS Biol 2018;16:e2002468. [PMID: 29702638 DOI: 10.1371/journal.pbio.2002468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
30 Shulman LM. Polio and Its Epidemiology. In: Kanki P, Grimes DJ, editors. Infectious Diseases. New York: Springer; 2013. pp. 237-308. [DOI: 10.1007/978-1-4614-5719-0_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Pan N, Liu B, Bao X, Zhang H, Sheng S, Liang Y, Pan H, Wang X. Oral Delivery of Novel Recombinant Lactobacillus Elicit High Protection against Staphylococcus aureus Pulmonary and Skin Infections. Vaccines (Basel) 2021;9:984. [PMID: 34579221 DOI: 10.3390/vaccines9090984] [Reference Citation Analysis]
32 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Stoyanova A, Nikolova I, Pürstinger G, Dobrikov G, Dimitrov V, Philipov S, Galabov AS. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice. Antivir Chem Chemother 2015;24:136-47. [PMID: 27815331 DOI: 10.1177/2040206616671571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
34 Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses: Poliovirus Transmission and Evolution Model. Risk Analysis 2013;33:703-49. [DOI: 10.1111/risa.12044] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 9.4] [Reference Citation Analysis]
35 Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. Vaccine 2015;33:6611-6. [PMID: 26529068 DOI: 10.1016/j.vaccine.2015.10.091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
36 Behrend MR, Hu H, Nigmatulina KR, Eckhoff P. A quantitative survey of the literature on poliovirus infection and immunity. Int J Infect Dis 2014;18:4-13. [PMID: 24246740 DOI: 10.1016/j.ijid.2013.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
37 Yakovenko ML, Korotkova EA, Ivanova OE, Eremeeva TP, Samoilovich E, Uhova I, Gavrilin GV, Agol VI. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J Virol 2009;83:3402-6. [PMID: 19129444 DOI: 10.1128/JVI.02122-08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
38 Yakovenko ML, Gmyl AP, Ivanova OE, Eremeeva TP, Ivanov AP, Prostova MA, Baykova OY, Isaeva OV, Lipskaya GY, Shakaryan AK, Kew OM, Deshpande JM, Agol VI. The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt. Euro Surveill 2014;19:20706. [PMID: 24576474 DOI: 10.2807/1560-7917.es2014.19.7.20706] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
39 Barrett S. Economic considerations for the eradication endgame. Philos Trans R Soc Lond B Biol Sci 2013;368:20120149. [PMID: 23798697 DOI: 10.1098/rstb.2012.0149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
40 Wilton T, Dunn G, Eastwood D, Minor PD, Martin J. Effect of formaldehyde inactivation on poliovirus. J Virol 2014;88:11955-64. [PMID: 25100844 DOI: 10.1128/JVI.01809-14] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
41 Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013;33:680-702. [PMID: 23470192 DOI: 10.1111/risa.12022] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 10.0] [Reference Citation Analysis]
42 Zhang Y, Li J, Li Q. Immune Evasion of Enteroviruses Under Innate Immune Monitoring. Front Microbiol 2018;9:1866. [PMID: 30154774 DOI: 10.3389/fmicb.2018.01866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
43 Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172:1213-29. [PMID: 20978089 DOI: 10.1093/aje/kwq320] [Cited by in Crossref: 243] [Cited by in F6Publishing: 188] [Article Influence: 22.1] [Reference Citation Analysis]
44 Faison WJ, Rostovtsev A, Castro-Nallar E, Crandall KA, Chumakov K, Simonyan V, Mazumder R. Whole genome single-nucleotide variation profile-based phylogenetic tree building methods for analysis of viral, bacterial and human genomes. Genomics 2014;104:1-7. [PMID: 24930720 DOI: 10.1016/j.ygeno.2014.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
45 Chumakov K, Ehrenfeld E, Agol VI, Wimmer E. Polio eradication at the crossroads. Lancet Glob Health 2021;9:e1172-5. [PMID: 34118192 DOI: 10.1016/S2214-109X(21)00205-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]